keyword
MENU ▼
Read by QxMD icon Read
search

Anthracycline

keyword
https://www.readbyqxmd.com/read/28648866/cytokines-in-immunogenic-cell-death-applications-for-cancer-immunotherapy
#1
REVIEW
Anne Showalter, Arati Limaye, Jeremiah L Oyer, Robert Igarashi, Christina Kittipatarin, Alicja J Copik, Annette R Khaled
Despite advances in treatments like chemotherapy and radiotherapy, metastatic cancer remains a leading cause of death for cancer patients. While many chemotherapeutic agents can efficiently eliminate cancer cells, long-term protection against cancer is not achieved and many patients experience cancer recurrence. Mobilizing and stimulating the immune system against tumor cells is one of the most effective ways to protect against cancers that recur and/or metastasize. Activated tumor specific cytotoxic T lymphocytes (CTLs) can seek out and destroy metastatic tumor cells and reduce tumor lesions...
June 22, 2017: Cytokine
https://www.readbyqxmd.com/read/28645798/left-atrial-mechanics-and-integrated-calibrated-backscatter-in-anthracycline-treated-long-term-survivors-of-childhood-cancers
#2
Vivian Wing-Yi Li, Clare Tik-Man Lai, Anthony Pak-Yin Liu, Daniel Ka-Leung Cheuk, Yiu-Fai Cheung
We tested the hypothesis that left atrial (LA) mechanics and myocardial calibrated integrated backscatter (cIB) are altered in anthracycline-treated long-term survivors of childhood cancers. Forty-nine survivors and 25 controls were studied. Survivors had significantly smaller maximal (p = 0.009) and minimal (p = 0.017) LA volumes and lower peak negative LA strains (p = 0.011). For left ventricular (LV) indices, survivors had significantly lower shortening fraction (p < 0.001), ejection fraction (p < 0...
June 20, 2017: Ultrasound in Medicine & Biology
https://www.readbyqxmd.com/read/28644154/acute-promyelocytic-leukemia-and-chronic-lymphocytic-leukemia-concomitant-presentation-of-two-molecularly-distinct-entities
#3
Jingdong Su, Diana Veillon, Rodney Shackelford, James Cotelingam, Hazem El-Osta, Glenn Mills, Reinhold Munker, Srinivas Devarakonda
Acute myeloid leukemia (AML) developing in patients with chronic lymphocytic leukemia (CLL) is very uncommon and usually associated with prior treatment. Acute promyelocytic leukemia (APL) accounts for a very small proportion of treatment-associated AML. So far, there has been only one reported case of APL occurring post radiation for prostate cancer in a patient with CLL. We report herein the first case of APL and CLL presenting concomitantly in an untreated patient. Evaluation of peripheral blood and bone marrow aspirate with immunohistochemistry, flow cytometry, and FISH to confirm two morphologically, molecularly and genetically distinct leukemic populations characteristic of APL and CLL is required...
May 2017: Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society
https://www.readbyqxmd.com/read/28643803/vhl-deficiency-augments-anthracycline-sensitivity-of-clear-cell-renal-cell-carcinomas-by-down-regulating-aldh2
#4
Yao-Hui Gao, Zhao-Xia Wu, Li-Qi Xie, Cai-Xia Li, Yu-Qin Mao, Yan-Tao Duan, Bing Han, San-Feng Han, Yun Yu, Hao-Jie Lu, Peng-Yuan Yang, Tian-Rui Xu, Jing-Lin Xia, Guo-Qiang Chen, Li-Shun Wang
The von Hippel-Lindau (VHL) is deficient in ∼70% of clear-cell renal cell carcinomas (ccRCC), which contributes to the carcinogenesis and drug resistance of ccRCC. Here we show that VHL-deficient ccRCC cells present enhanced cytotoxicity of anthracyclines in a hypoxia-inducible factor-independent manner. By subtractive proteomic analysis coupling with RNAi or overexpression verification, aldehyde dehydrogenase 2 (ALDH2) is found to be transcriptionally regulated by VHL and contributes to enhanced anthracyclines cytotoxicity in ccRCC cells...
June 15, 2017: Nature Communications
https://www.readbyqxmd.com/read/28642833/creating-a-biomarker-panel-for-early-detection-of-chemotherapy-related-cardiac-dysfunction-in-breast-cancer-patients
#5
Krithika Srikanthan, Rebecca Klug, Maria Tirona, Ellen Thompson, Haresh Visweshwar, Nitin Puri, Joseph Shapiro, Komal Sodhi
Cardiotoxicity is an important issue for breast cancer patients receiving anthracycline-trastuzumab therapy in the adjuvant setting. Studies show that 3-36% of patients receiving anthracyclines and/or trastuzumab experience chemotherapy related cardiac dysfunction (CRCD) and approximately 17% of patients must stop chemotherapy due to the consequences of CRCD. There is currently no standardized, clinically verified way to detect CRCD early, but common practices include serial echocardiography and troponin measurements, which can be timely, costly, and not always available in areas where health care resources are scarce...
March 2017: Journal of Clinical & Experimental Cardiology
https://www.readbyqxmd.com/read/28641315/sequential-vs-concurrent-epirubicin-and-docetaxel-as-adjuvant-chemotherapy-for-high-risk-node-negative-early-breast-cancer-an-interim-analysis-of-a-randomised-phase-iii-study-from-the-hellenic-oncology-research-group
#6
Dimitrios Mavroudis, Emmanouil Saloustros, Ioannis Boukovinas, Pavlos Papakotoulas, Stylianos Kakolyris, Nikolaos Ziras, Charalampos Christophylakis, Nikolaos Kentepozidis, Georgios Fountzilas, Georgios Rigas, Ioannis Varthalitis, Konstantinos Kalbakis, Sofia Agelaki, Dora Hatzidaki, Vasilios Georgoulias
BACKGROUND: Sequential anthracyclines and taxanes are standard adjuvant chemotherapy for patients with high-risk axillary node-positive breast cancer. We compared a sequential to a concurrent regimen in high-risk node-negative early breast cancer. METHODS: Patients were eligible if they had tumours >2 cm or T1c with two of the following characteristics: no oestrogen receptor (ER) and progesterone receptor (PR) expression, histological grade III, Ki67 >40% and vascular, lymphovascular or perineural invasion...
June 22, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28641095/high-dose-chemotherapy-and-autologous-stem-cell-transplantation-in-relapsed-or-refractory-hodgkin-lymphoma-emerging-questions-newer-agents-and-changing-paradigm
#7
REVIEW
Saad Akhtar
Primary treatment for adult and pediatric patients with Hodgkin lymphoma (HL) using current multiagent anthracycline-based chemotherapy with or without radiation therapy will cure approximately >70% of the patients; >95% for early stage with a favorable risk profile and 70-75% with advanced stage and high risk features. Managing refractory and relapsed disease, however, remains a challenge. High dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT) can salvage 40-70% of patients with relapsed or refractory HL...
June 13, 2017: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/28639910/apatinib-for-metastatic-breast-cancer-in-non-clinical-trial-setting-satisfying-efficacy-regardless-of-previous-anti-angiogenic-treatment
#8
Ying Lin, Zheng Wu, Jian Zhang, Xichun Hu, Zhonghua Wang, Biyun Wang, Jun Cao, Leiping Wang
Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2. This study aimed to evaluate the efficacy and safety of apatinib in metastatic breast cancer (MBC) under non-clinical trial setting, and to study the impact of previous antiangiogenic treatment to the efficacy of apatinib. 52 MBC patients treated with apatinib under non-clinical trial setting in Fudan University Shanghai Cancer Center between January 1st 2015 and October 1st 2016 were included. All patients were included in time-to-treatment failure (TTF) analysis, while 45 patients were enrolled for progression-free survival (PFS) and overall survival (OS) analysis because 7 of the patients with treatment discontinuation due to intolerable toxicities had too short time for efficacy assessment...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28636290/sulforaphane-protection-against-the-development-of-doxorubicin-induced-chronic-heart-failure-is-associated-with-nrf2-upregulation
#9
Yang Bai, Qiang Chen, Yun-Peng Sun, Xuan Wang, Li Lv, Li-Ping Zhang, Jin-Sha Liu, Song Zhao, Xiao-Lu Wang
Doxorubicin (DOX) is an anthracycline anti-tumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity, and even progresses to chronic heart failure (CHF). OBJECTIVE: This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. METHODS: Male Sprague Dawley rats who received treatment for six weeks were divided into four groups (n=30 per group): control, SFN, DOX, and DOX plus SFN group. RESULTS: Results revealed that DOX induced progressive cardiac damage as indicated by increased cardiac injury markers, cardiac inflammation, fibrosis and oxidative stress...
June 21, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28632729/radiation-associated-breast-cancer-and-gonadal-hormone-exposure-a-report-from-the-childhood-cancer-survivor-study
#10
Chaya S Moskowitz, Joanne F Chou, Charles A Sklar, Dana Barnea, Cécile M Ronckers, Danielle Novetsky Friedman, Joseph P Neglia, Lucie Turcotte, Rebecca M Howell, Tara O Henderson, Gregory T Armstrong, Wendy M Leisenring, Leslie L Robison, Flora E van Leeuwen, Malcolm C Pike, Kevin C Oeffinger
BACKGROUND: The relationship between hormone exposure and breast cancer risk in women treated with chest radiotherapy for childhood cancer is uncertain. METHODS: Participants included 1108 females from the Childhood Cancer Survivor Study who were diagnosed with childhood cancer 1970-1986, treated with chest radiotherapy, and survived to ages ⩾20 years. Hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox models adjusted for chest radiation field, delivered dose, anthracycline exposure, and age at childhood cancer estimated risk...
June 20, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28629059/versatile-quarto-stimuli-nanostructure-based-on-trojan-horse-approach-for-cancer-therapy-synthesis-characterization-in-vitro-and-in-vivo-studies
#11
Eleni K Efthimiadou, Eirini Fragogeorgi, Lazaros Palamaris, Theodoros Karampelas, Pavlos Lelovas, George Loudos, Constantin Tamvakopoulos, Nikolaos Kostomitsopoulos, George Kordas
Nanostructured delivery and diagnostic systems that induces specific targeting properties by exploiting the local physicochemical tumour characteristics will be evaluated is the present work. It is well known that cancer cells have specific physicochemical characteristics, which can be taken into consideration for the design of a broad spectrum of drug delivery systems (DDS). Some of those characteristics including the different temperature environment their susceptibility when temperature ranges between 40 and 43°C where cell apoptosis is induced, the intra- and extra-cellular pH which varies from 6...
October 1, 2017: Materials Science & Engineering. C, Materials for Biological Applications
https://www.readbyqxmd.com/read/28625376/electrocardiographic-abnormalities-and-mortality-in-aging-survivors-of-childhood-cancer-a-report-from-the-st-jude-lifetime-cohort-study
#12
Daniel A Mulrooney, Elsayed Z Soliman, Matthew J Ehrhardt, Lu Lu, Daniel A Duprez, Russell V Luepker, Gregory T Armstrong, Vijaya M Joshi, Daniel M Green, Deokumar Srivastava, Matthew J Krasin, G Stephen Morris, Leslie L Robison, Melissa M Hudson, Kirsten K Ness
BACKGROUND: Electrocardiography (ECG), predictive of adverse outcomes in the general population, has not been studied in cancer survivors. We evaluated the prevalence of ECG abnormalities and associations with mortality among childhood cancer survivors. METHODS: Major and minor abnormalities were coded per the Minnesota Classification system for participants in the St Jude Lifetime Cohort Study (n = 2,715) and community controls (n = 268). Odds ratios (ORs) and 95% CIs were calculated using multivariable logistic regression; and hazard ratios, using Cox proportional hazards regression...
July 2017: American Heart Journal
https://www.readbyqxmd.com/read/28622153/extraskeletal-osteosarcoma-outcomes-and-the-role-of-chemotherapy
#13
Jonas Paludo, Karen Fritchie, Candace L Haddox, Peter S Rose, Carola A S Arndt, Randolph S Marks, Evanthia Galanis, Scott H Okuno, Steven I Robinson
OBJECTIVES: Extraskeletal osteosarcoma (EO) is a malignant neoplasm that produces osteoid, bone, and chondroid material without direct attachment to bone or periosteum. Surgical resection is the mainstay of treatment; the role of chemotherapy is not well defined. Therefore, we evaluated the impact of chemotherapy in the survival of patients with EO. METHODS: All EO patients seen at Mayo Clinic between 1990 and 2014 were assessed. Forty-three patients were included after all archived pathology slides were reviewed to confirm the diagnosis of EO...
June 15, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28621491/outcome-of-patients-older-than-80%C3%A2-years-with-diffuse-large-b-cell-lymphoma-dlbcl-treated-with-standard-immunochemotherapy-a-large-retrospective-study-from-4-institutions
#14
Stefania Gobba, Alden A Moccia, Wiebke Gulden-Sala, Annarita Conconi, Stefan Diem, Luciano Cascione, Gloria Iacoboni, Gloria Margiotta-Casaluci, Kathrin Aprile von Hohenstaufen, Anastasios Stathis, Felicitas Hitz, Graziella Pinotti, Gianluca Gaidano, Emanuele Zucca
Little information is available on the very elderly patients with diffuse large B-cell lymphoma (DLBCL). We performed a retrospective analysis of 281 patients >80 years old with newly diagnosed DLBCL treated in 4 referral institutions in Switzerland and Northern Italy. Primary end points were overall survival, progression-free survival, and cause-specific survival. Systemic chemotherapy was given to 239 patients, and 119 of them received rituximab in their initial treatment. At a median follow-up of 5.5 years, 5-year progression-free survival was 26% (95% confidence interval [CI], 20-32%), 5-year overall survival was 31% (95% CI, 25-37%), and 5-year cause-specific survival was 48% (95% CI, 41-55%) for the entire cohort...
June 16, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28621163/eribulin-in-advanced-liposarcoma-and-leiomyosarcoma
#15
Elisabetta Setola, Jonathan Noujaim, Charlotte Benson, Sant Chawla, Emanuela Palmerini, Robin L Jones
The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challenge. Consequently, one of the main research goals is to define specific tailored therapy for each histological subtype and to develop a more personalised approach to treatment. The standard first line chemotherapy for advanced STS is doxorubicin, with or without ifosfamide, however, a number of different drugs are emerging as active therapies beyond first-line. Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial...
June 16, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28618329/therapy-of-older-persons-with-acute-myeloid-leukaemia
#16
REVIEW
Utz Krug, Robert Peter Gale, Wolfgang E Berdel, Carsten Müller-Tidow, Matthias Stelljes, Klaus Metzeler, M Cristina Sauerland, Wolfgang Hiddemann, Thomas Büchner
Most persons age≥60 y with acute myeloid leukaemia (AML) die from their disease. When interpreting clinical trials data from these persons one must be aware of substantial selection biases. Randomized trials of post-remission treatments can be performed upfront or after achieving defined landmarks. Both strategies have important limitations. Selection of the appropriate treatment is critical. Age, performance score, co-morbidities and frailty provide useful data to treatment selection. If an intensive remission induction therapy is appropriate, therapy with cytarabine and an anthracycline is the most common regimen...
June 1, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28612225/prolonged-survival-in-patients-with-breast-cancer-and-a-history-of-brain-metastases-results-of-a-preplanned-subgroup-analysis-from-the-randomized-phase-iii-beacon-trial
#17
Javier Cortés, Hope S Rugo, Ahmad Awada, Chris Twelves, Edith A Perez, Seock-Ah Im, Patricia Gómez-Pardo, Lee S Schwartzberg, Veronique Diéras, Denise A Yardley, David A Potter, Audrey Mailliez, Alvaro Moreno-Aspitia, Jin-Seok Ahn, Carol Zhao, Ute Hoch, Mary Tagliaferri, Alison L Hannah, Joyce O'Shaughnessy
PURPOSE: Conventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. METHODS: The phase 3 BEACON trial enrolled 852 women with heavily pretreated locally recurrent or metastatic breast cancer between 2011 and 2013...
June 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28611540/evaluation-of-qtc-interval-prolongation-in-breast-cancer-patients-after-treatment-with-epirubicin-cyclophosphamide-and-docetaxel-and-the-influence-of-interobserver-variation
#18
Julian Puppe, Deborah van Ooyen, Jeanne Neise, Fabinshy Thangarajah, Christian Eichler, Stefan Krämer, Roman Pfister, Peter Mallmann, Marina Wirtz, Guido Michels
BACKGROUND: Chemotherapy with anthracyclines is associated with life-threatening electrocardiographic alterations including corrected QT (QTc) interval prolongation. PATIENTS AND METHODS: In this study we assessed the effect of epirubicin, cyclophosphamide, and docetaxel (EC-Doc) on the QTc interval in 10 patients with early breast cancer. Cardiac toxicity was assessed with symptoms, transthoracic echocardiography, electrocardiography (ECG), and serum cardiac markers at baseline and after 4 cycles of EC and 4 cycles of docetaxel...
March 2017: Breast Care
https://www.readbyqxmd.com/read/28611280/efficacy-of-adjuvant-chemotherapy-with-carboplatin-for-early-triple-negative-breast-cancer-a-single-center-experience
#19
Marcus Vetter, Spyridon Fokas, Ewelina Biskup, Thomas Schmid, Fabienne Schwab, Andreas Schoetzau, Uwe Güth, Christoph Rochlitz, Rosanna Zanetti-Dällenbach
BACKGROUND: Anthracycline- and taxane-based adjuvant chemotherapies are the most frequently used systemic treatments for women with triple negative breast cancer (TNBC). Adding platinum derivatives in the neo-adjuvant setting has been shown to not only improve the pCR rates, but also the 3 year DFS for TNBC patients; however, data on platinum derivatives in the adjuvant setting are limited. METHODS: We conducted a retrospective, single-center study in a Swiss breast cancer cohort to evaluate the role of carboplatin in addition to standard adjuvant therapy (anthracyclines and/ or taxanes) in early TNBC patients...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28611109/an-in-vivo-functional-screen-identifies-jnk-signaling-as-a-modulator-of-chemotherapeutic-response-in-breast-cancer
#20
Matthew Ashenden, Antoinette van Weverwijk, Nirupa Murugaesu, Antony Fearns, James Campbell, Qiong Gao, Marjan Iravani, Clare M Isacke
Chemotherapy remains the mainstay of treatment for advanced breast cancer, however, resistance is an inevitable event for the majority of patients with metastatic disease. Moreover, there is little information available to guide stratification of first line chemotherapy, crucial given the common development of multidrug resistance. Here we describe an in vivo screen to interrogate the response to anthracycline-based chemotherapy in a syngeneic metastatic breast cancer model, and identify JNK signaling as a key modulator of chemotherapy response...
June 13, 2017: Molecular Cancer Therapeutics
keyword
keyword
12198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"